In Depth
Hi, I’m your pharmacist!
Hi, I’m your pharmacist and I’m not ignoring you it’s just that I’m pretty focused on my job at the moment Although you may not really understand all that this …
Research Roundup
Debbie Rigby rounds up the latest in research news Respiratory syncytial virus in children Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory tract infection …
60 day dispensing KPIs
Over six months have passed since the implementation of sixty-day dispensing. It’s time to start monitoring your pharmacy’s performance during the transition, says Victoria Le In a recent LinkedIn video, …
Skill and judgement needed on opium
An impersonation scandal, the fate of “Rat Biskett” and some tips on opium for smoking all made the news in April 1904 That month, we reported on a special meeting …
Transitions of care
Why pharmacists are a critical part of the aged care puzzle, say Fei Sim and Laetitia Hattingh With Australia’s ageing population and increased healthcare needs, the seamless transition between hospital, …
Research Roundup
Debbie Rigby rounds up the latest in research news Embedded on-site aged care pharmacists in Australia This study highlights the resident- and system-level roles and benefits of embedded on-site pharmacists, …
Dealing with pharmacy’s ‘Bermuda Triangle’
Pharmacy owners must make sure that their space investment works well, but are they stocking the right categories to maximise their returns? Bermuda is a British overseas territory in the …
Opioids, overdose and naloxone: starting the conversation
Risk factors for overdose are surprisingly common among patients taking prescribed opioids, but how can pharmacists best approach conversations around safety and prevention? Sheshtyn Paola investigates Most people know that …
‘Nothing matters as long as the price is cheaper’
To everything there is a season, the AJP wrote in 1964 – as the season of weighing up professional quality against price came around again W.R.Cutler wrote a guest editorial …
April MIMS update
We look at some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Fezolinetant (Veoza) is a nonhormonal selective NK3 receptor antagonist that …
Investment ratings houses cool on Sigma/CWH deal
Evidence is growing that some institutional advisors may be starting to grow wary of the CWH/Sigma deal, says Mike Taylor When financial advisers make investment recommendations to clients they are …
Research Roundup
Debbie Rigby rounds up the latest in research news Treatment of chronic insomnia in adults Despite guidelines recommending nonpharmacologic methods as the primary strategy to treat chronic insomnia, medications are …
